ICONICON is a global provider of outsourced drug development and commercialisation services to biopharma, medical device, government, biosimilar and generic organisations.
With over 600 vaccine specialists, ICON has supported 11 vaccine approvals and has experience in over 200 vaccine clinical trials, including three ‘mega-trials’ with over 10,000 subjects each.
ICON Government and Public Health Solutions provide full service clinical development and staffing services across multiple agencies in the US Government, and have extensive experience working with multi-national public health organizations and global NGOs.
ICON has been awarded ‘Best in Class’ CRO in vaccine research by the World Vaccine Congress in both 2017 and 2014, and have been highly commended or shortlisted the last six years.
With headquarters in Dublin, Ireland, ICON currently operates from 97 locations in 38 countries and has approximately 13,250 employees
Visit www.iconplc.com/vaccines
